Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?

European Journal of Cancer, Supplement

Volumn 2, Issue 2, 2004, Pages 20-28

  Aapro, M ^a   Bajetta, E ^a   Freund, M ^a   Littlewood, T J ^a   Nortier, J W R ^a   Rapoport, B ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Anemia; Chemotherapy; Epoetin alfa; Quality of life; Tumor hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANALYTIC METHOD; ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; ENERGY; FATIGUE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; TRANSFUSION;

EID: 2442419193     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00104-6     Document Type: Conference Paper

References (25)

1. Albain K.S., Crowley J.J., LeBlanc M., Livingston R.B. Survival determinants in extensive-stage non-small-cell lung cancer. the Southwest Oncology Group experience J. Clin. Oncol. 9:1991;1618-1626
2. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
3. Molls M., Stadler P., Becker A., Feldmann H.J., Dunst J. Relevance of oxygen in radiation oncology. Strahlenther. Onkol. 174(Suppl. 4):1998;13-16
4. Ohlhauser C., Bulzebruck H., Ebert W., Drings P., Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer. a multivariate regression analysis of 456 patients with radiatiotherapy Onkologie. 20:1997;126-131
5. Höckel M., Schlenger K., Aral B., Mitze M., Schäffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515
6. Sutherland R.M. Tumor hypoxia and gene expression - implications for malignant progression and therapy. Acta Oncol. 37:1998;567-574
7. Vaupel P., Kelleher D.K., Höckel M. Oxygen status of malignant tumors. pathogenesis of hypoxia and significance for tumor therapy Semin. Oncol. 28(Suppl. 8):2001;29-35
8. Höckel M., Vaupel P. Tumor hypoxia. definitions and current clinical, biologic, and molecular aspects J. Natl. Cancer Inst. 93:2001;266-276
9. Teicher B.A., Holden S.A., al-Achi A., Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 50:1990;3339-3344
10. Grau C., Overgaard J. Significance of hemoglobin concentrations for treatment outcome. Molls M., Vaupel P. Blood Perfusion and Microenvironment of Human Tumors. Implications for Clinical Radiooncology. 1998;101-112 Berlin, Springer-Verlag
11. Ludwig H., Fritz E., Leitgeb C., Krainer M., Kuhrer I., Sagaster P., Umek H. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann. Oncol. 4:1993;161-167
12. Soignet S. Management of cancer-related anemia. epoetin alfa and quality of life Semin. Hematol. 37(Suppl. 6):2000;9-13
13. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. for the Procrit Study Group Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15:1997;1218-1234
14. Demetri G.D., Kris M., Wade J., Degos L., Cella D. for the Procrit Study Group Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16:1998;3412-3425
15. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients. improvements in Hb and quality of life are similar to three-times-weekly dosing J. Clin. Oncol. 19:2001;2875-2882
16. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. for the Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2874
17. Crawford J., Cella D., Cleeland C.S., et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 95:2002;888-895
18. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 75:1998;800-802
19. Cox D.R. Regression models and life tables [with discussion]. J. Royal Statist. Soc. 34(series B):1972;187-220
20. Abels R.I. Recombinant human erythropoietin in the treatment of the anemia of cancer. Acta Haematol. 87(Suppl. 1):1992;4-11
21. Henry D.H., Abels R.I. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia. results of double-blind and open-label follow-up studies Semin. Oncol. 21(Suppl. 3):1994;21-28
22. Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 73:1994;2535-2542
23. Ludwig H., Fritz E., Kotzmann H., Hocker P., Gisslinger H., Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322:1990;1693-1699
24. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 86:1999;1528-1536
25. Caro J.J., Salas M., Ward A., Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. a systemic, quantitative review Cancer. 91:2001;2214-2221